Paper2351925
The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non-randomized controlled study.
Olsson AG and 2 others. J Intern Med, 1990. Cited by 43 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non-randomized controlled study. Papers, record 2351925. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2351925
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non-randomized controlled study.
- PubMed
Topics18
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Arteriosclerosis | Major topic |
| Diet | Major topic |
| Femoral Artery | Major topic |
| Hyperlipidemias | Major topic |
| Lipids | Major topic |
| Niacin | Major topic |
| Adult | |
| Analysis of Variance | |
| Blood Pressure | |
| Cholesterol, VLDL | |
| Combined Modality Therapy | |
| Drug Evaluation | |
| Humans | |
| Hyperlipoproteinemias | |
| Male | |
| Middle Aged | |
| Radiography | |
| Smoking |
Source PubMed
Cited by7
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 43 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 11,122,726 | Niacin dosing: relationship to benefits and adverse effects. | Curr Atheroscler Rep | 2000 | https://conductscience.org/library/papers/11122726 | PubMed |
| 9,205,850 | Management of lipid disorders in the elderly. | Drugs Aging | 1997 | https://conductscience.org/library/papers/9205850 | PubMed |
| 8,920,175 | Age-related changes affecting atherosclerotic risk. Potential for pharmacological intervention. | Drugs Aging | 1996 | https://conductscience.org/library/papers/8920175 | PubMed |
| 8,110,618 | Lowering blood lipids to treat atherosclerosis: vascular tone, plaques, events, and mortality. | Cardiovasc Drugs Ther | 1993 | https://conductscience.org/library/papers/8110618 | PubMed |
| 8,043,977 | Fenofibrate improves postprandial chylomicron clearance in II B hyperlipoproteinemia. | Clin Investig | 1994 | https://conductscience.org/library/papers/8043977 | PubMed |
| 1,576,071 | A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia. | Br J Clin Pharmacol | 1992 | https://conductscience.org/library/papers/1576071 | PubMed |
| 1,390,323 | Cholesterol and coronary disease--outstanding questions. | Cardiovasc Drugs Ther | 1992 | https://conductscience.org/library/papers/1390323 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/2351925
GET https://conductscience.org/api/papers/v1/2351925/authors